NF2 and non-small cell lung carcinoma: For this, we selected two patient-derived xenograft (PDX) models of NF2 mutant NSCLC cells, as we observed TEADi-MEKi synergism in both NSCLC and mesothelioma cell lines in vitro (Figs. 5, EV5 and EV6), and Hippo mutant mesothelioma cells either did not form tumors in mice or were unsuitable for in vivo combination therapy experiments as they were extremely sensitive to TEADi monotherapy (Tang et al, 2021).